A complex neurological disorder characterized by recurrent episodes of moderate-to-severe headache (typically unilateral, pulsating, 4-72 hours duration), often preceded by aura, accompanied by nausea, photophobia, and phonophobia. Involves cortical spreading depression, neurovascular dysfunction, neuroinflammation, and altered sensory processing with strong immune, gut microbiome, and mitochondrial components. Represents a systems-level mismatch between ancestral energy-stable environments and modern stressor loads.
Imagine a city power grid that's been running on borderline capacity for months. The power plant (mitochondria) is struggling, the surge protectors (magnesium, antioxidant systems) are worn out, and the transformer stations (trigeminal ganglia) are hypersensitive. One day, a small electrical fluctuation ripples across the grid β maybe a storm (stress), a factory starting up (certain foods releasing histamine or tyramine), or a sudden power demand spike (oestrogen drop in menstrual cycle). This triggers a cascading blackout that spreads across one hemisphere of the city (cortical spreading depression).
As the blackout spreads, emergency alarms go off at the main transformer station (Trigeminal nerve nucleus), which releases a flood of emergency signals (CGRP, Substance P). These signals cause the blood vessels to dilate (trying to deliver more fuel), but they also activate the city's inflammatory response β fire trucks (mast cells), emergency crews (microglia), all converging and releasing smoke signals (IL-6, TNF-Ξ±, prostaglandins). The smoke itself becomes part of the problem, making the whole system more sensitive. Meanwhile, the sewage system (gut microbiome) has been producing too much toxic waste (histamine, not enough SCFA), which keeps the whole grid on edge. The blackout eventually resolves, but the infrastructure is left damaged, making the next blackout easier to trigger.
Migraine pathophysiology involves multiple interacting systems:
- Neuronal depolarization wave spreads across cortex at 2-6 mm/min
- KβΊ and glutamate release into extracellular space β massive depolarization
- Triggers transient oligemia followed by hyperemia
- Activates TRPV1 and TRPA1 channels on trigeminal nerve endings
- CSD β activation of matrix metalloproteinases (MMPs) β blood-brain barrier disruption
- ATP release β P2X3 receptor activation on trigeminal afferents
ΒΆ Trigeminal Activation and CGRP Release
- CSD activates trigeminal nerve terminals innervating meningeal vessels
- Trigeminal ganglia release CGRP (37-amino acid neuropeptide)
- CGRP binds to calcitonin receptor-like receptor (CALCRL) + receptor activity-modifying protein 1 (RAMP1)
- CGRP β vasodilation via nitric oxide (NO) and prostaglandin pathways
- CGRP β mast cell degranulation β histamine, TNF-Ξ±, IL-6, tryptase release
- Substance P co-release β NK1 receptor activation β further neurogenic inflammation
- Meningeal mast cells degranulate β release histamine, serotonin, cytokines
- Dural neutrophils and macrophages activated β IL-1Ξ², IL-6, TNF-Ξ±
- Microglial activation in trigeminal nucleus caudalis β amplification of pain signals
- COX-2 upregulation β PGE2 production β sensitization of nociceptors
- NF-ΞΊB activation β transcription of pro-inflammatory genes
- Breakdown of blood-brain barrier β plasma protein extravasation
- Genetic variants in mitochondrial DNA (especially in Complex I genes)
- Energy deficit β reduced NaβΊ/KβΊ-ATPase function β neuronal hyperexcitability
- Oxidative stress β lipid peroxidation β membrane instability
- Impaired CoQ10, riboflavin (FAD), magnesium availability
- Reduced ATP β failure of ion pumps β easier depolarization threshold
- Oestrogen withdrawal (menstrual migraine) β reduced GABAergic tone
- Oestrogen β modulation of CGRP receptor expression
- Progesterone β GABA_A receptor potentiation (protective)
- Cortisol β modulation of inflammatory response and pain threshold
graph TD
A["Trigger: Stress, Food, Hormones, Sleep"] --> B[Cortical Spreading Depression]
B --> C["Glutamate + K+ Release"]
C --> D[Trigeminal Nerve Activation]
D --> E[CGRP Release]
E --> F["Vasodilation + Mast Cell Degranulation"]
F --> G[Neurogenic Inflammation]
G --> H["IL-6, TNF-Ξ±, PGE2"]
H --> I[Central Sensitization]
J[Gut Dysbiosis] --> K[Reduced SCFA, High Histamine]
K --> L[Systemic Inflammation]
L --> G
M[Mitochondrial Dysfunction] --> N[Energy Deficit]
N --> B
N --> O[Oxidative Stress]
O --> G
P[Oestrogen Fluctuation] --> B
P --> E
I --> Q["Pain Perception + Sensory Hypersensitivity"]
In cPNI practice, migraine is approached as a multi-system disorder reflecting evolutionary mismatch between ancestral energy stability and modern metabolic/inflammatory stressors. This perspective fundamentally changes intervention strategies.
Clinical Presentation Patterns:
- Prodrome (24-48h before): fatigue, irritability, food cravings, neck stiffness
- Aura (25% of cases): visual scotoma, sensory changes, speech difficulties
- Headache phase: unilateral (60%), pulsating, 4-72h, aggravated by activity
- Postdrome: "migraine hangover" lasting 24-48h
Metamodel Integration:
- Metabolic System: Energy deficit and mitochondrial dysfunction as primary driver
- Selfish Brain: Brain prioritizes its own glucose/oxygen supply β triggers vasodilation
- Immune-Brain Axis: Neuroinflammation and mast cell involvement central to pathology
- Gut-Brain Axis: Microbiome composition directly influences attack frequency
- Evolutionary Mismatch: Modern triggers (processed foods, artificial light, chronic stress) vs. ancestral physiology
Key Clinical Thresholds:
- CGRP levels during attack: 40-120 pg/mL (baseline: <20 pg/mL)
- Calprotectin (fecal): >50 ΞΌg/g suggests gut inflammation component
- Magnesium (RBC): optimal >5.0 mg/dL (deficiency in 50% of migraineurs)
- Vitamin D: <30 ng/mL associated with increased frequency
- Homocysteine: >10 ΞΌmol/L suggests methylation pathway dysfunction
- Omega-3 Index: <8% associated with higher inflammatory tone
Intervention Priorities:
- Mitochondrial support: CoQ10 300mg, riboflavin 400mg, magnesium 400-600mg daily
- Anti-inflammatory diet: Eliminate histamine-rich foods, tyramine, gluten, processed foods
- Gut microbiome optimization: Increase SCFA producers, reduce histamine producers
- Barrier restoration: Zinc carnosine, glutamine, omega-3 fatty acids
- Stress axis regulation: Adaptogen support, vagal tone optimization
- Hormone balancing: Address oestrogen dominance in menstrual-related cases
- Sleep optimization: Regular sleep-wake cycles, darkness exposure
Pharmaceutical Context:
- CGRP antagonists (erenumab, fremanezumab) reduce attack frequency by 50% in 30-50% of patients
- NSAIDs block COX-2 β reduce PGE2 production
- Triptans (5-HT1B/1D agonists) β vasoconstriction + CGRP release inhibition
- Beta-blockers β reduce cortical hyperexcitability
- However, cPNI approach addresses root causes rather than just blocking mediators
Comorbidity Patterns (suggest shared mechanisms):
- Affects 15% of global population; 3:1 female:male ratio (hormonal modulation)
- Genetic heritability: 40-60% (polygenic: MTHFR, COMT, TRPV1, mitochondrial DNA variants)
- Four phases: prodrome (24-48h) β aura (5-60 min) β headache (4-72h) β postdrome (24-48h)
- CGRP is 37-amino acid neuropeptide; levels increase 2-6-fold during attack
- Cortical spreading depression travels at 2-6 mm/min across cortex
- 50% of migraineurs have magnesium deficiency (RBC magnesium <5.0 mg/dL)
- Riboflavin 400mg daily reduces attack frequency by 50% after 3 months
- CoQ10 300mg daily comparable efficacy to topiramate with better tolerability
- Gut microbiome differences: reduced Faecalibacterium prausnitzii, increased Enterobacteriaceae
- Histamine threshold significantly lower in migraineurs (DAO enzyme often reduced)
- Menstrual migraine affects 60% of female migraineurs (oestrogen withdrawal trigger)
- 25-30% experience aura; visual auras most common (90%)
- Triggers: stress (80%), dietary factors (27%), sleep disruption (50%), hormonal changes (65%)
- New CGRP monoclonal antibodies reduce monthly migraine days by 4-7 days on average
- Chronic migraine defined as β₯15 headache days per month, β₯8 with migraine features
- Economic burden: >$36 billion annually in US (direct + indirect costs)
- CGRP β primary neuropeptide mediator; drives vasodilation and neurogenic inflammation in migraine
- Cortical spreading depression β initiating wave of depolarization that triggers aura and trigeminal activation
- Trigeminal nerve β cranial nerve V; meningeal branches activated by CSD release CGRP and Substance P
- Neurogenic inflammation β CGRP-driven cascade causing meningeal vessel dilation and pain
- Mast Cell Degranulation β releases histamine, TNF-Ξ±, tryptase amplifying neuroinflammation
- Microglial activation β in trigeminal nucleus caudalis perpetuates central sensitization
- Central sensitization β enhanced pain processing in CNS; shared with fibromyalgia, chronic pain
- Gut-brain axis β dysbiotic microbiome influences attack frequency via SCFA, histamine, serotonin
- Gut microbiome β reduced Faecalibacterium, increased Enterobacteriaceae alter inflammatory tone
- SCFA β butyrate deficiency linked to increased neuroinflammation and attack susceptibility
- Histamine β dietary and microbial histamine trigger attacks; DAO deficiency common
- Serotonin β 95% gut-derived; reduced availability linked to migraine susceptibility
- GABA β gut bacterial GadB enzyme produces GABA; reduced in dysbiosis
- Blood-brain barrier β disrupted by MMP activation during CSD; allows inflammatory mediator entry
- Mitochondrial dysfunction β energy deficit lowers depolarization threshold; genetic variants common
- Magnesium β cofactor for 300+ enzymes; deficiency in 50% of migraineurs; stabilizes membranes
- CoQ10 β electron transport chain component; supplementation reduces attack frequency
- Oestrogen β withdrawal during menstrual cycle triggers attacks; modulates CGRP receptor expression
- Stress β #1 trigger (80%); activates HPA axis, depletes magnesium, impairs mitochondrial function
- Sleep β disruption triggers attacks via circadian misalignment and metabolic instability
- Depression β 45% comorbidity; shared neuroinflammation and monoamine dysregulation
- Anxiety β common comorbidity; shared threat detection and stress axis dysfunction
- Irritable bowel syndrome β 30-50% comorbidity; shared gut-brain axis pathology
- Fibromyalgia β shared central sensitization, neuroinflammation, mitochondrial issues
- Chronic fatigue syndrome β overlapping mitochondrial dysfunction and immune activation
- IL-6 β elevated during attacks; correlates with pain intensity
- TNF-Ξ± β released by mast cells and microglia; drives neuroinflammation
- Prostaglandins β PGE2 from COX-2 sensitizes nociceptors; NSAIDs block this pathway
- COX-2 β upregulated during attacks; target of acute migraine treatment
- NF-ΞΊB β master inflammatory transcription factor activated in migraine cascade
- TRPV1 β capsaicin receptor on trigeminal endings; activated by CSD
- TRPA1 β mechanosensitive channel; activated by oxidative stress and inflammation
- Nitric Oxide β CGRP-induced vasodilator; NO donors trigger migraine in susceptible individuals
- LPS β bacterial endotoxin from gut dysbiosis; TLR4 activation amplifies inflammation
- TLR4 β pattern recognition receptor; activated by LPS and endogenous DAMPs
- Oxidative Stress β mitochondrial dysfunction generates ROS; perpetuates neuroinflammation
- ATP β energy deficit from mitochondrial dysfunction; also DAMP activating inflammation
- Glutamate β excitatory neurotransmitter; excess during CSD drives depolarization
- P2X3 Receptor β ATP-gated ion channel on trigeminal afferents; amplifies pain signals
- Chronic inflammation β systemic low-grade inflammation lowers migraine threshold
- Neuroinflammation β localized brain inflammation central to migraine pathophysiology